Suven Life secures two product patents in Australia and Canada

Suven Life Sciences Ltd has received two product patents -one from Australia and another from Canada - on new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases, the company announced today.

Suven Life said the product patent from Australia (2012311057) and the one from Canada (2827567) are valid through 2032 and 2031, respectively.

''The granted claims of the patent from Australia include the class of selective 5-HT4 compounds and the granted claims of the patent from Canada is through mechanism of action – H3 Inverse agonist and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia,'' the company stated in a release.

With these new patents, Suven has a total of 23 granted patents from Australia and 22 granted product patents from Canada. ''These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts,'' Suven said.

The company plans to license out these inventions at various phases of clinical development like at Phase-I or Phase-II.

''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally'' said Venkat Jasti, CEO of Suven.

Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition, the company has 10 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.